| The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery HG Stunnenberg, S Abrignani, D Adams, M de Almeida, L Altucci, V Amin, ... Cell 167 (5), 1145-1149, 2016 | 522 | 2016 |
| TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration D Palacios, C Mozzetta, S Consalvi, G Caretti, V Saccone, V Proserpio, ... Cell stem cell 7 (4), 455-469, 2010 | 441 | 2010 |
| Histone deacetylation in epigenetics: an attractive target for anticancer therapy A Mai, S Massa, D Rotili, I Cerbara, S Valente, R Pezzi, S Simeoni, ... Medicinal research reviews 25 (3), 261-309, 2005 | 419 | 2005 |
| BLUEPRINT to decode the epigenetic signature written in blood D Adams, L Altucci, SE Antonarakis, J Ballesteros, S Beck, A Bird, C Bock, ... Nature biotechnology 30 (3), 224-226, 2012 | 380 | 2012 |
| Sirtuin functions and modulation: from chemistry to the clinic V Carafa, D Rotili, M Forgione, F Cuomo, E Serretiello, GS Hailu, E Jarho, ... Clinical epigenetics 8, 1-21, 2016 | 354 | 2016 |
| Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2 C Binda, S Valente, M Romanenghi, S Pilotto, R Cirilli, A Karytinos, ... Journal of the American Chemical Society 132 (19), 6827-6833, 2010 | 347 | 2010 |
| Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect E Lara, A Mai, V Calvanese, L Altucci, P Lopez-Nieva, ... Oncogene 28 (6), 781-791, 2009 | 301 | 2009 |
| Oxidative stress and epigenetic regulation in ageing and age-related diseases C Cencioni, F Spallotta, F Martelli, S Valente, A Mai, AM Zeiher, ... International journal of molecular sciences 14 (9), 17643-17663, 2013 | 271 | 2013 |
| HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment C Colussi, C Mozzetta, A Gurtner, B Illi, J Rosati, S Straino, G Ragone, ... Proceedings of the National Academy of Sciences 105 (49), 19183-19187, 2008 | 269 | 2008 |
| SIRT5 regulation of ammonia-induced autophagy and mitophagy L Polletta, E Vernucci, I Carnevale, T Arcangeli, D Rotili, S Palmerio, ... Autophagy 11 (2), 253-270, 2015 | 266 | 2015 |
| Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead A Mai, L Altucci The international journal of biochemistry & cell biology 41 (1), 199-213, 2009 | 262 | 2009 |
| The emerging role of epigenetics in human autoimmune disorders R Mazzone, C Zwergel, M Artico, S Taurone, M Ralli, A Greco, A Mai Clinical epigenetics 11, 1-15, 2019 | 250 | 2019 |
| Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue A Galmozzi, N Mitro, A Ferrari, E Gers, F Gilardi, C Godio, G Cermenati, ... diabetes 62 (3), 732-742, 2013 | 249 | 2013 |
| Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides A Mai, S Massa, R Pezzi, S Simeoni, D Rotili, A Nebbioso, ... Journal of medicinal chemistry 48 (9), 3344-3353, 2005 | 241 | 2005 |
| Targeting histone demethylases: a new avenue for the fight against cancer D Rotili, A Mai Genes & cancer 2 (6), 663-679, 2011 | 237 | 2011 |
| Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors A Mai, S Massa, S Lavu, R Pezzi, S Simeoni, R Ragno, FR Mariotti, ... Journal of medicinal chemistry 48 (24), 7789-7795, 2005 | 209 | 2005 |
| Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors JH Kalin, M Wu, AV Gomez, Y Song, J Das, D Hayward, N Adejola, M Wu, ... Nature communications 9 (1), 53, 2018 | 203 | 2018 |
| HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer EA Stronach, A Alfraidi, N Rama, C Datler, JB Studd, R Agarwal, ... Cancer research 71 (13), 4412-4422, 2011 | 201 | 2011 |
| Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors A Mai, S Valente, S Meade, V Carafa, M Tardugno, A Nebbioso, ... Journal of medicinal chemistry 52 (17), 5496-5504, 2009 | 182 | 2009 |
| Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ... EMBO reports 10 (7), 776-782, 2009 | 174 | 2009 |
